Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative therapy
for many hematologic and immunologic diseases. Further, partial or full donor hematopoietic
chimerism following alloSCT may be sufficient to guarantee immunologic tolerance to solid
organs from the same donor, obviating any requirement for prolonged pharmacologic
immunosuppression. Despite alloSCT's potential, the procedure is beset by two major
limitations. The first relates to the procedure's toxicity, including conditioning regimen …